Advertisement
UK markets close in 7 hours 16 minutes

  • FTSE 100

    8,058.59
    +34.72 (+0.43%)
     

  • FTSE 250

    19,689.29
    +89.90 (+0.46%)
     

  • AIM

    752.03
    +2.85 (+0.38%)
     

  • GBP/EUR

    1.1576
    -0.0013 (-0.11%)
     

  • GBP/USD

    1.2358
    +0.0008 (+0.07%)
     

  • Bitcoin GBP

    53,405.18
    +8.39 (+0.02%)
     

  • CMC Crypto 200

    1,393.19
    -21.57 (-1.52%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.66
    +0.76 (+0.93%)
     

  • GOLD FUTURES

    2,320.70
    -25.70 (-1.10%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,831.30
    +319.61 (+1.94%)
     

  • DAX

    17,979.19
    +118.39 (+0.66%)
     

  • CAC 40

    8,057.23
    +16.87 (+0.21%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Freeline to Participate in Stifel 2021 Virtual Healthcare Conference

Freeline Therapeutics
·1-min read

LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Stifel 2021 Virtual Healthcare Conference. Freeline Chief Executive Officer Michael Parini is scheduled to participate in a Fireside Chat at the event on November 15, 2021 at 1:20 p.m. ET.

A webcast of the Fireside Chat will be available on the Investors section of the Freeline website for 90 days. Senior management will participate in virtual one-on-one meetings with investors at the conference on November 16.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Contact

David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947